DETAILS, FICTION AND TRACLEER

6 The phosphodiesterase-five inhibitor sildenafil is certified for PAH in FC I–IV in the United states and FC II–III in Europe. Endothelin receptor antagonists (ERAs) including bosentan, sitaxentan and ambrisentan are oral therapies certified for use in PAH. As no oral agent has demonstrated superiority there continues to be discussion regardin